Daniel G. Chain

Daniel G. Chain has extensive work experience in the biopharmaceutical industry. Daniel G. currently serves as the President & CEO of TauC3 Biologics Limited, a British biopharmaceutical company focusing on developing a monoclonal antibody for the treatment of Alzheimer's disease and Progressive Supranuclear Palsy. Prior to this, they were the Founder and Chief Scientific Officer of CereSpir Incorporated, where they worked on developing innovative treatments for neurodegenerative disorders. Daniel G. also served as the Chairman & CEO of Intellect Neurosciences Inc., a biopharmaceutical company focused on developing therapeutic drugs for neurological diseases. Earlier in their career, they were the President & CEO of Mindset BioPharmaceuticals (USA) Inc. Overall, Daniel G. Chain has a strong background in biopharmaceutical research and leadership.

Daniel G. Chain obtained a PhD in Biochemistry from the Weizmann Institute of Science, completing their studies from 1984 to 1991.